Asymmetrically substituted cationic indole- and fluorene porphyrins inhibit tumor proliferation in small intestinal neuroendocrine tumors and medullary thyroid carcinomas

European Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2010, Pages 760-773

  Haeubl, Martin ^b   Schuerz, Susanne ^b   Svejda, Bernhard ^a   Reith, Lorenz Michael ^b   Gruber, Bernadette ^b   Pfragner, Roswitha ^a   Schoefberger, Wolfgang ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b JOHANNES KEPLER UNIVERSITY LINZ   (Austria)

Author keywords

Cationic porphyrins; Cytotoxicity; DNA intercalators; Fluorene; Indole; KRJ I; MTC SK; Neuroendocrine tumors; Water soluble

Indexed keywords

5 [5 [2 (9,9 DIMETHYL)FLUORENYL] N METHYLPYRIDINIUM 3 YL] 10,15,20 TRIS(N METHYLPYRIDINIUM 4 YL) 21H,23H PORPHYRIN CHLORIDE; 5,10,5 TRIS(N METHYLPYRIDINIUM 4 YL) 20 [1 PHENYL 4 (3 N PHENYLSULFONYLINDOLYL)] 21H,23H PORPHYRIN CHLORIDE; FLUORENE DERIVATIVE; INDOLE DERIVATIVE; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL COUNT; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; NEUROENDOCRINE TUMOR; SMALL INTESTINE TUMOR; STEREOCHEMISTRY; SUBSTITUTION REACTION; THYROID MEDULLARY CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CATTLE; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; FLUORENES; HUMANS; INDOLES; NEUROENDOCRINE TUMORS; PORPHYRINS; SOLUBILITY; THYROID NEOPLASMS; WATER;

EID: 73549096419     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.11.025     Document Type: Article

References (60)

1. Dolmans D.E., Fukumura D., and Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer 3 (2003) 380-387
2. Brown S.B., Brown E.A., and Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 5 (2004) 497-508
3. Moan J., and Peng Q. An outline of the hundred-year history of PDT. Anticancer Res. 23 (2003) 3591-3600
4. Triesscheijn M., Baas P., Schellens J.H., and Stewart F.A. Photodynamic therapy in oncology. Oncologist 11 (2006) 1034-1044
5. Rhodes L.E., Rie M.A.d., Leifsdottir R., Yu R.C., Bachmann I., Goulden V., Wong G.A., Richard M.A., Anstey A., and Wolf P. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch. Dermatol. 143 (2007) 1131-1136
6. Christensen E., Skogvoll E., Viset T., Warloe T., and Sundstrom S. Photodynamic therapy with 5-aminolaevulinic acid, dimethylsulfoxide and curettage in basal cell carcinoma: a 6-year clinical and histological follow-up. J. Eur. Acad. Dermatol. Venereol. 23 (2009) 58-66
7. Loewen G.M., Pandey R., Bellnier D., Henderson B., and Dougherty T. Endobronchial photodynamic therapy for lung cancer. Lasers Surg. Med. 38 (2006) 364-370
8. Moghissi K., and Dixon K. Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer?. Eur. Respir. J. 22 (2003) 535-541
9. Moghissi K., Dixon K., Thorpe J.A., Stringer M., and Oxtoby C. Photodynamic therapy (PDT) in early central lung cancer: a treatment option for patients ineligible for surgical resection. Thorax 62 (2007) 391-395
10. Dunn J., and Lovat L. Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus. Expert Opin. Pharmacother. 9 (2008) 851-858
11. Filonenko E.V., Sokolov V.V., Chissov V.I., Lukyanets E.A., and Vorozhtsov G.N. Photodynamic therapy of early esophageal cancer. Photodiagnosis. Photodyn. Ther. 5 (2008) 187-190
12. Radu A., Grosjean P., Fontolliet C., Wagnieres G., Woodtli A., Bergh H.V., and Monnier P. Photodynamic therapy for 101 early cancers of the upper aerodigestive tract, the esophagus, and the bronchi: a single-institution experience. Diagn. Ther. Endosc. 5 (1999) 145-154
13. Buytaert E., Dewaele M., and Agostinis P. Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim. Biophys. Acta 1776 (2007) 86-107
14. Castano A.P., Mroz P., and Hamblin M.R. Photodynamic therapy and anti-tumour immunity. Nat. Rev. Cancer 6 (2006) 535-545
15. Castano A.P. Mechanisms in photodynamic therapy: part two cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn. Ther. 2 (2005) 1-23
16. Pratviel G., Bernadou J., Ricci M., and Meunier B. Magnesium monoperoxophtalate: an efficient single oxygen atom donor in DNA cleavage catalyzed by metalloporphyrin. Biochem. Biophys. Res. Commun. 160 (1989) 1212-1218
17. Tjahjono D.H., Yamamoto T., Ichimoto S., Yoshioka N., and Inoue H. Synthesis and DNA-binding properties of bisdiazoliumylporphyrins. J. Chem. Soc. Perkin Trans. 1 (2000) 3077-3081
18. Mukundan N.E., Petho G., Dixon D.W., Kim M.S., and Marzilli L.G. Interactions of an electron-rich tetracationic tentacle porphyrin with calf thymus DNA. J. Inorg. Chem. 33 (1994) 4676-4687
19. Mukundan N.E., Petho G., Dixon D.W., Kim M.S., and Marzilli L.G. DNA-tentacle porphyrin interactions: AT over GC selectivity exhibited by an outside binding self-stacking porphyrin. J. Inorg. Chem. 34 (1995) 3677-3687
20. Sari M.A., Battioni J.P., Dupre D., Mansuy D., and Lepecq J.B. Mode of interaction and apparent binding constants of meso-tetraaryl porphyrins bearing between one and four positive charges with DNA. Biochem. Biophys. Res. Commun. 141 (1986) 643-649
21. Hudson B.P., Sou J., Berger J.D., and McMillin D.R. Luminescence studies of the intercalation of Cu(TMpyP4) into DNA. J. Am. Chem. Soc. 114 (1992) 8997-9002
22. Sari M.A., Battioni J.P., Dupre D., Mansuy D., and Lepecq J.B. Interaction of cationic porphyrins with DNA: importance of the number and position of the charges and minimum structural requirements for intercalation. Biochemistry 29 (1990) 4205-4215
23. Butje K., and Nakamoto K. Interaction of water-soluble Cu(II), Ni(II), and Co(III) porphyrins with polynucleotides. J. Inorg. Biochem. 39 (1990) 75-92
24. Chirvony V.S., Galievsky V.A., Terekhov S.N., Dzhagarov B.M., Ermolenkov V.V., and Turpin P.-Y. Binding of the cationic 5-coordinate Zn(II)-5,10,15,20-tetrakis(4-N-methylpyridyl)porphyrin to DNA and model polynucleotides: ionic-strength dependent intercalation in [poly(dG-dC)]2. Biospectroscopy 5 (1999) 302-312
25. Gray T.A., Yue K.T., and Marzilli L.G. Effect of N-alkyl substituents on the DNA binding properties of meso-tetrakis (4-N-alkylpyridinium-4-yl)porphyrins and their nickel derivatives. J. Inorg. Biochem. 41 (1991) 205-219
26. Manono J., Marzilli P.A., and Marzilli L.G. New porphyrins bearing positively charged peripheral groups linked by a sulfonamide group to meso-tetraphenylporphyrin: interactions with calf thymus DNA. Inorg. Chem. 48 (2009) 5636-5647
27. Guliaev A.B., and Leontis N.B. Cationic 5,10,15,20-tetrakis(N-methylpyridinium-4-yl)porphyrin fully intercalates at 5′-CG-3′ steps of duplex DNA in solution. Biochemistry 38 (1999) 15425-15437
28. Pasternack R.F., Gibbs E.J., and Villafranca J.J. Interactions of porphyrins with nucleic acids. Biochemistry 22 (1983) 2406-2414
29. Pfragner R., Wirnsberger G., Niederle B., Behmel A., Rinner I., Mandl A., Wawrina F., Luo J.S., Adamiker D., Höger H., Ingolic E., and Schauenstein K. Establishment of a continuous cell line from a human carcinoid of the small intestine (KRJ-I): characterization and effects of 5-azacytidine on proliferation. Int. J. Oncol. 8 (1996) 513-520
30. Pfragner R., Höfler H., Behmel A., Ingolic E., and Walser V. Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res. 50 (1990) 4160-4166
31. Wolf C., Lederer K., Pfragner R., Schauenstein K., Ingolic E., and Siegl V. Biocompatibility of ultra-high molecular weight polyethylene (UHMW-PE) stabilized with alpha-tocopherol used for joint endoprostheses assessed in vitro. J. Mater. Sci.: Mater. Med. 18 (2007) 1247-1252
32. Modlin I.M., Oberg K., Chung D.C., Jensen R.T., Herder W.W.d., Thakker R.V., Caplin M., Fave G.D., Kaltsas G.A., Krenning E.P., Moss S.F., Nilsson O., Rindi G., Salazar R., Ruszniewski P., and Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9 (2008) 61-72
33. Toni R. The neuroendocrine system: organization and homeostatic role. J. Endocrinol. Invest. 27 (2004) 35-47
34. Modlin I.M., Lye K.D., and Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 (2003) 934-959
35. Modlin I.M., Kidd M., Latich I., Zikusoka M.N., and Shapiro M.D. Current status of gastrointestinal carcinoids. Gastroenterology 128 (2005) 1717-1751
36. Modlin I.M., Latich I., Kidd M., Zikusoka M., and Eick G. Therapeutic options for gastrointestinal carcinoids. Clin. Gastroenterol. Hepatol. 4 (2006) 526-547
37. Hoff A.O., and Hoff P.M. Medullary thyroid carcinoma. Hematol. Oncol. Clin. North. Am. 21 (2007) 475-488
38. Jimenez C., Hu M.I., and Gagel R.F. Management of medullary thyroid carcinoma. Endocrinol. Metab. Clin. North. Am. 37 (2008) 481-496
39. Tuttle R.M., and Leboeuf R. Investigational therapies for metastatic thyroid carcinoma. J. Natl. Compr. Canc. Netw. 5 (2007) 641-646
40. W. Schoefberger, M. Haeubl, Synthesis of new asymmetrically meso-substituted water-soluble porphyrins acting as cytostatic agents, in: E. Patent (Ed.), 2009, pp. 80.
41. Casas C., Saint-Jalmes B., Loup C., Lacey C.J., and Meunier B. Synthesis of cationic metalloporphyrin precursors related to the design of DNA cleavers. J. Org. Chem. 58 (1993) 2913-2917
42. Robic N., Bied-Charreton C., Perrée-Fauvet M., Verchère-Béaur C., Salmon L., Gaudemer A., and Pasternack R.F. Synthesis and preliminary DNA-interaction studies of a new cationic porphyrin. Tetrahedron Lett. 33 (1990)
43. Hambright P., Gore T., and Burton M. Synthesis and characterization of new isomeric water-soluble porphyrins. tetra(2-N-methylpyridy1)porphine and tetra(3-N-methylpyridyl)porphine. Inorg. Chem. 15 (1976) 2314-2315
44. Suzuki A. Suzuki coupling. Metal-catalyzed Cross-coupling Reactions (2004), Wiley-VCH, New York
45. Lottner C., Knuechel R., Bernhardt G., and Brunner H. Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells. Cancer Lett. 215 (2004) 167-177
46. Seidl J., Rauch J., Krieg R.C., Appel S., Baumgartner R., and Knuechel R. Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid-induced protoporphyrin IX as sensitizer. Int. J. Cancer 92 (2001) 671-677
47. Svensson J., Johansson A., Grafe S., Gitter B., Trebst T., Bendsoe N., Andersson-Engels S., and Svanberg K. Tumor selectivity at short times following systemic administration of a liposomal temoporfin formulation in a murine tumor model. Photochem. Photobiol. 83 (2007) 1211-1219
48. Westerman P., Glanzmann T., Andrejevic S., Braichotte D.R., Forrer M., Wagnieres G.A., Monnier P., van den Bergh H., Mach J.P., and Folli S. Long circulating half-life and high tumor selectivity of the photosensitizer meta-tetrahydroxyphenylchlorin conjugated to polyethylene glycol in nude mice grafted with a human colon carcinoma. Int. J. Cancer 76 (1998) 842-850
49. Plaetzer K., Kiesslich T., Oberdanner C.B., and Krammer B. Apoptosis following photodynamic tumor therapy: induction, mechanisms and detection. Curr. Pharm. Des. 11 (2005) 1151-1165
50. Nseyo U.O. Photodynamic therapy in the management of bladder cancer. J. Clin. Laser Med. Surg. 14 (1996) 271-280
51. Schenkman E., and Lamm D.L. Superficial bladder cancer therapy. Scientific World J. 4 Suppl. 1 (2004) 387-399
52. Plaetzer K., Kiesslich T., Krammer B., and Hammerl P. Characterization of the cell death modes and the associated changes in cellular energy supply in response to AlPcS4-PDT. Photochem. Photobiol. Sci. 1 (2002) 172-177
53. Berridge M.V., Tan A.S., McCoy K.D., and Wang R. The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica 4 (1996) 15-19
54. Acharya S., Dilnawaz F., and Sahoo S.K. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30 (2009) 5737-5750
55. Cui X., Zhou S., Xu H., Zhao T., Liu A., Guo X., and Wang F. Reversal effects of hyaluronan oligosaccharides on adriamycin resistance of K562/A02 cells. Anticancer Drugs 20 (2009) 800-806
56. Knauer S., Biersack B., Zoldakova M., Effenberger K., Milius W., and Schobert R. Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M. Anticancer Drugs 20 (2009) 676-681
57. Tian Q., Zhang J., Chan S.Y., Tan T.M., Duan W., Huang M., Zhu Y.Z., Chan E., Yu Q., Nie Y.Q., Ho P.C., Li Q., Ng K.Y., Yang H.Y., Wei H., Bian J.S., and Zhou S.F. Topotecan is a substrate for multidrug resistance associated protein 4. Curr. Drug Metab. 7 (2006) 105-118
58. Zhang R., Niu Y., and Zhou Y. Increase the cisplatin cytotoxicity and cisplatin-induced DNA damage in HepG2 cells by XRCC1 abrogation related mechanisms. Toxicol. Lett. (2009)
59. Ngamwongsatit P., Banada P.P., Panbangred W., and Bhunia A.K. WST-1-based cell cytotoxicity assay as a substitute for MTT-based assay for rapid detection of toxigenic Bacillus species using CHO cell line. J. Microbiol. Methods 73 (2008) 211-215
60. Niles A.L., Moravec R.A., Eric Hesselberth P., Scurria M.A., Daily W.J., and Riss T.L. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal. Biochem. 366 (2007) 197-206